FDA Clears Quest's Respiratory Virus Molecular Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing a molecular respiratory virus test made by Quest Diagnostics' Focus Diagnostics business, the firm said today.

The agency granted 510(k) clearance for the Focus Diagnostics Simplexa Flu A/B & RSV test for use on the 3M Integrated Cycler. The Simplexa RT-PCR test is intended to aid in the detection and discrimination of influenza A, influenza B, and respiratory syncytial virus infections.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."